ARGX
HOLD / NEUTRALNeutralComposite
60.20
Technical
58.20
Fundamental
61.60
Rank
—
Price
888.82
Hurst
0.41
As of
Jul 28, 2026
Daily
argenx SE
HealthcareBiotechnologyargenx SE is a biopharmaceutical company developing therapies for autoimmune and related disorders, with operations across the United States, Japan, China, and Europe. The company markets VYVGART and VYVGART HYTRULO for conditions including generalized myasthenia gravis, immune thrombocytopenia, and related inflammatory neuropathies, while maintaining a pipeline of investigational antibody-based treatments targeting various immune and inflammatory pathways. The company collaborates with multiple partners on drug development and commercialization efforts.
Market cap
$56.1B
P/E (trailing)
30.93
P/E (forward)
26.80
PEG ratio
1.20
Dividend yield
0.00%
Beta
-0.04
52w range
661.85 – 1,072.75
Return on equity
—
Profit margin
+31.73%
Revenue growth
+52.10%
Earnings growth
+50.60%
Price history
1Y: 892.87 (+9.1%) · range 663.93–1,058.90
Cycle position
47/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 28 · NOT READY · exit proximity 0
Conviction
31/ 100 · maturity 86%
VScore.3621
Buildup.2128
EMA entry setup.2728
Fundamentals.1662
Volume profile
POC
873.67
Price vs POC
+2.2%
Overhead supply
40%
Runway
open sky
Value area 799.39–930.13 · 40% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.237 | Oct 30, 2026 |
| financial-news | 0.120 | Oct 23, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +16.88% | +19.21% | mature |
| 40d | +8.44% | +21.40% | mature |